Poseida Therapeutics Stock Probability of Future Stock Price Finishing Over 9.31

PSTX Stock  USD 9.31  0.02  0.21%   
Poseida Therapeutics' future price is the expected price of Poseida Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Poseida Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Poseida Therapeutics Backtesting, Poseida Therapeutics Valuation, Poseida Therapeutics Correlation, Poseida Therapeutics Hype Analysis, Poseida Therapeutics Volatility, Poseida Therapeutics History as well as Poseida Therapeutics Performance.
For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.
  
At this time, Poseida Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price To Book Ratio is likely to rise to 4.84 in 2024, whereas Price To Sales Ratio is likely to drop 4.45 in 2024. Please specify Poseida Therapeutics' target price for which you would like Poseida Therapeutics odds to be computed.

Poseida Therapeutics Target Price Odds to finish over 9.31

The tendency of Poseida Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 9.31 90 days 9.31 
near 1
Based on a normal probability distribution, the odds of Poseida Therapeutics to move above the current price in 90 days from now is near 1 (This Poseida Therapeutics probability density function shows the probability of Poseida Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.66 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Poseida Therapeutics will likely underperform. In addition to that Poseida Therapeutics has an alpha of 3.2885, implying that it can generate a 3.29 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Poseida Therapeutics Price Density   
       Price  

Predictive Modules for Poseida Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Poseida Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Poseida Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.469.2738.38
Details
Intrinsic
Valuation
LowRealHigh
0.509.9239.03
Details
Naive
Forecast
LowNextHigh
0.2411.9141.02
Details
5 Analysts
Consensus
LowTargetHigh
11.1512.2513.60
Details

Poseida Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Poseida Therapeutics is not an exception. The market had few large corrections towards the Poseida Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Poseida Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Poseida Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
3.29
β
Beta against Dow Jones2.66
σ
Overall volatility
1.41
Ir
Information ratio 0.12

Poseida Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Poseida Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Poseida Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Poseida Therapeutics is way too risky over 90 days horizon
Poseida Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 64.7 M. Net Loss for the year was (123.43 M) with loss before overhead, payroll, taxes, and interest of (22.41 M).
Poseida Therapeutics currently holds about 142.56 M in cash with (92.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66.
Poseida Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 58.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Poseida shares surge on 1.5 billion Roche acquisition deal

Poseida Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Poseida Stock often depends not only on the future outlook of the current and potential Poseida Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Poseida Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding90.2 M
Cash And Short Term Investments212.2 M

Poseida Therapeutics Technical Analysis

Poseida Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Poseida Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Poseida Therapeutics. In general, you should focus on analyzing Poseida Stock price patterns and their correlations with different microeconomic environments and drivers.

Poseida Therapeutics Predictive Forecast Models

Poseida Therapeutics' time-series forecasting models is one of many Poseida Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Poseida Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Poseida Therapeutics

Checking the ongoing alerts about Poseida Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Poseida Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Poseida Therapeutics is way too risky over 90 days horizon
Poseida Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 64.7 M. Net Loss for the year was (123.43 M) with loss before overhead, payroll, taxes, and interest of (22.41 M).
Poseida Therapeutics currently holds about 142.56 M in cash with (92.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66.
Poseida Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 58.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Poseida shares surge on 1.5 billion Roche acquisition deal

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.